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Sir,
Thank you for the opportunity to reply to the issues raised in the
letter by Dr Zahl regarding our paper (Bucchi et al, 2005).
The study focused on the potential for biological progression of
screen-detected (SD) breast cancers. In brief, we assumed the
following: (1) the average risk of axillary lymph node metastases is
lower for SD cases than clinical cases; (2) nodal status is the
product of biological aggressiveness and chronological age of the
disease; (3) tumour size is a proxy indicator of chronological age;
and (4) specifically for SD tumours, size is an indicator of duration
of preclinical phase. The hypothesis was that the relative
protection of SD tumours from the risk of nodal involvement
(i.e. their relative biological indolence) decreases with increasing
size. We built a multiple regression model that included a term for
the detection-mode-by-tumour-size interaction. This was strong
and significant. The relative risk of nodal involvement for SD
tumours increased from 0.05 in the 2–7mm size category to 0.95
in the 18–22mm category, while decreasing again among the
relatively small number of SD tumours of larger size. We found
only one plausible and coherent interpretation of such a pattern,
namely (1) the biological aggressiveness of most breast cancers
increases during the preclinical phase; (2) only a small subset of
screen-detected cancers have a relatively stable biological indo-
lence; and (3) they become apparent only among the few large-
sized tumours detected at first screen.
Dr Zahl suggests that the length time bias and its extreme form,
overdiagnosis, may explain those observations. In particular, he
disagrees with our statement that ‘yno published data support an
inverse association between overdiagnosis and tumour sizey’.
Length bias and overdiagnosis in mammography screening are not
under debate. Their potential magnitude, however, is ill-defined.
The probability of slow-growing SD tumours being classified as
overdiagnosed is closely dependent on duration of follow-up. In
the greater part of published estimates, the ratio of the lifetime
cumulative number of cases in a screened population to the
number in a control population varies between zero (Olsen et al,
2003) and 20% (Wald et al, 1994). When we wrote the paper we did
not know yet of the work by Zahl et al (2004), who reported an
excess incidence as high as 50%. It is beyond the scope of this brief
note to address the methodological concerns that have been raised
regarding the design of that study. In brief, as stated by Duffy in an
accompanying Editorial (2005), it seems unlikely that the
length bias could entirely explain the interaction effect observed
in our data.
In any case, the magnitude of length bias (and of overdiagnosis,
if any) is not the key to the interpretation of our findings. A much
more critical question is: are slow-growing tumours equally
distributed by size? In fact, length bias may explain the observed
downward trend in the relative risk of nodal metastases only if it is
assumed that the prevalence of slow-growing SD cancers decreases
with increasing tumour size. The problem is more complicated than
it appears. As cancers overdiagnosed are SD, and SD cancers are
relatively small, it is conceivable to conclude that there is an
ecological association between overdiagnosis and small lesions.
However, it does not follow that the prevalence of overdiagnosis is
inversely related to tumour size. If the rate of onset of new slow-
growing tumours is constant, the prevalence of such cases is not
expected to be greater among SD cancers 2–7mm in size than it is
in the 18–22mm category. In fact, we are not aware of any reported
observation suggesting this association in a formal fashion.
Assuming that the onset of new slow-growing tumours follows a
constant rate, the next question is: what may cause the prevalence
of indolent SD tumours to decrease with size? As Dr Zahl will
certainly remember, we took into consideration the hypothesis that
the natural prevalence of indolent cancers among those SD is
altered by mammography itself, that is, that mammography
sensitivity decreases selectively for such lesions as their size
increases. Such a hypothesis is clearly implausible: not only has it
never been demonstrated, the issue has never even been raised. We
also discussed another potential type of overdiagnosis, namely, the
histological misinterpretation of benign lesions as malignant. In
fact, it is not reasonable to assume that such a shortcoming occurs
more often among SD cancers than clinical cancers of the same
size. Nor it is likely that histology evaluation is less accurate in the
breast surgery reference hospitals involved in screening. If the
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remains: the prevalence of indolent lesions decreases because of
tumour progression.
We did not cite the investigation by Joensuu et al (2004) because
its end point, tumour size-specific survival of SD cancers
compared with clinical cancers, was not closely relevant to the
design of our own. We acknowledge, however, that findings in that
study were consistent with the relative biological indolence of SD
tumours being a constant feature. The only point we make is that
Joensuu et al categorized tumour size into conventional 10-mm
categories, whereas our case series could only be categorized into
clusters around multiples of 5mm (Figure 1 in the paper). It is
worth noting that our conclusion that the biological aggressiveness
of most breast cancers increases as they develop in size relies
critically on the key observation that SD cancers 18–22mm in
diameter had the same risk of lymph node involvement as clinical
cancers. If we had used the conventional cutoff value of 20mm,
these cases would have been equally diluted among those in
the lower and higher size categories, both with fewer nodal
metastases than clinical cancers of the same size. Incidentally, we
agree with the remark made by Duffy (2005) in the accompanying
Editorial. The practical implications of the observed frequency
distribution of tumour size go far beyond our speculations about
the impact of mammography on the natural history of breast
cancer.
We thank Dr Zahl for his comments. As a closing consideration,
however, we would like to emphasise that a thorough debate on the
meaning of our findings is rather premature. Prior to our study,
only a few univariate observations had suggested that tumour size
interacts with detection mode in determining the risk of lymph
node metastases (Anderson et al, 1991; Ernst et al, 2002). The only
previous study formally aimed at demonstrating this effect (Tabar
et al, 1987) had negative results. As pointed out by Duffy (2005),
our findings are unique and await confirmation.
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